ABSTRACT
Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study we address the impact of CAR density on the functionality of BCMA-CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with upregulation of exhaustion markers, increased in vitro cytotoxicity but a decrease in in vivo BM infiltration. Characterization of Gene Regulatory Networks using scRNA-seq identified regulons associated to activation and exhaustion upregulated in CARHigh T cells, providing mechanistic insights behind differential functionality of these cells. Finally, we demonstrate that patients treated with CAR T cell products enriched in CARHigh T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with significant impact on clinical response.
Teaser High CAR molecule density affects CAR T cell activity and associates with impaired clinical response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Instituto de Salud Carlos III co-financed by European Regional Development Fund-FEDER A way to make Europe (PI19/00669, ICI19/00025 and ICI19/00069). Red de Terapia Celular TERCEL (RD16/0011/0005). Redes de Investigacion Cooperativa Orientada a Resultados en Salud RICORS (RD21/0017/0009 and RD21/0017/0019). Centro de Investigacien Biomedica en Red de Cancer CIBERONC (CB16/12/00369 and CB16/12/00489). Ministerio de Ciencia e Innovacion co-financed by European Regional Development Fund-FEDER A way to make Europe (RTC-2017-6578-1 and PID2019-108989RB-I00.). European Commission (H2020-JTI-IMI2-2019-18: Contract 945393; SC1-PM-08-2017: Contract 754658; and H2020-MSCA-IF-2019: Grant Agreement 898356). Gobierno de Navarra (AGATA: 0011-1411-2020-000011 and 0011-1411-2020-000010; DESCARTHeS: 0011-1411-2019-000079 and 0011-1411-2019-000072; alloCART-LMA: PC011-012). Fundacion La Caixa (CP042702). Asociacion Espanola Contra el Cancer-AECC (LABAE21971FERN). Paula and Rodger Riney Foundation. Paula Rodriguez-Marquez was supported by FPU grant (FPU19/06160) from Ministerio de Universidades.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Hospital Clinic de Barcelona gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ These authors share senior authorship
Data Availability
All data produced in the present study are available upon reasonable request to the authors
